https://www.selleckchem.com/products/WP1130.html
Blinatumomab is a valuable bridging salvage therapy for relapsed or refractory patients to a second or even third HSCT. Despite heavy pretreatment of most of our patients, severe adverse events were rare and response rates encouraging. Blinatumomab is a valuable bridging salvage therapy for relapsed or refractory patients to a second or even third HSCT.Karnofsky performance status (KPS), a measure of physical frailty, predicts pre-transplant and post-transplant outcomes in liver transplantation, but has not been assessed in simultaneous
Like
Comment
Share
